Printer Friendly Printed from http://www.researchandmarkets.com/reports/354463 Emerging Therapies to Treat Lupus Erythematosus Description: Introduction Lupus erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptoms—and there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication. Get the Answers You Need to Shape Your Strategy The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrollment for clinical trials can be diffi cult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges? Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a signifi cant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current first-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater efficacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies’ modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies? Scope Etiology, pathophysiology, and prevalence: relationship of cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus (SLE); prevalence of systemic lupus erythematosus in the three major-market regions by gender. Current therapies: overview of leading therapies for CLE and for SLE. Indications covered: CLE (discoid LE), acute CLE, subacute CLE, and SLE. Emerging therapies: overview of agents for development for CLE and SLE; late-stage agents are discussed in detail. Market outlook: challenges that emerging agents will face and their prospects for success. Therapies mentioned inside this report include: - Abatacept - Abetimus sodium - Acitretin - Amcinonide - ASF-1096 - Azathioprine - Belimumab - Betamethasone - diproprionate - Celecoxib - Chloroquine - Clobetasol proprionate - Cyclophosphamide - Dapsone - Difl orasone diacetate - Edratide - Efalizumab - Epratuzumab - Etretinate - Hydroxychloroquine - Intravenous gamma - globulin - Isotretinoin - Lefl unomide - Methotrexate - Mycophenolate mofetil - Pimecrolimus - Prasterone - Rituximab - Sirolimus - Tacrolimus - Thalidomide - Triamcinolone acetonide Contents: Executive Summary Strategic Considerations Stakeholder Implications Introduction Cutaneous Lupus Erythematosus Disease Description and Etiology Prevalence Connection Between Cutaneous LE and Systemic LE Overview of Current Drug Therapies Corticosteroids Antimalarials Calcineurin Inhibitors Anti-Leprosy Agents Retinoids Systemic Lupus Erythematosus Disease Symptoms and Etiology Prevalence Overview of Current Drug Therapies Nonsteroidal Anti-Inflammatory Agents Corticosteroids Immunosuppressive/Immunomodulatory Agents Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus Genentech’s Efalizumab Astion Pharma’s ASF-1096 Emerging Therapies for the Treatment of Systemic Lupus Erythematosus Immunomodulators Aspreva/Roche’s Mycophenolate Mofetil Wyeth’s Sirolimus Astellas’s Tacrolimus Biological Agents Genentech/Biogen Idec’s Rituximab UCB/Immunomedics’ Epratuzumab Human Genome Science/GlaxoSmithKline’s Belimumab Bristol-Myers Squibb’s Abatacept Teva’s Edratide Other Approaches Genelabs Technologies’ Prasterone La Jolla Pharmaceutical’s Abetimus Sodium Outlook Tables 1. Current Therapies for the Treatment of Cutaneous Lupus Erythematosus 2. American College of Rheumatology Criteria for Classification of Systemic Lupus Erythematosus 3. Prevalent Cases of Systemic Lupus Erythematosus in the Three Major-Market Regions by Gender, 2005 4. Current Therapies for the Treatment of Systemic Lupus Erythematosus 5. Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus 6. Emerging Therapies for the Treatment of Systemic Lupus Erythematosus Figures 1. Onset and Complications of Systemic Lupus Erythematosus 2. Immunopathological Targets of Emerging Biological Therapies for Systemic Lupus Erythematosus 3. Emerging Agents for SLE Approved or In Development for Other Indications Companies Mentioned - Active Biotech - Allergan - Altana - Amgen - Aspreva - Astellas - Astion Pharma - Barr - Baxter - Biogen Idec - Biomarin - Boehringer Ingelheim - Bradley Pharmaceuticals - Bristol-Myers Squibb - Celgene - Connetics - Daiichi Sankyo - Duramed - Elusys Therapeutics - Genelabs Technologies - Genentech - GlaxoSmithKline - Human Genome Sciences - Immunomedics - ImmuPharma - La Jolla Pharmaceuticals - Meda - MedImmune - Merck - Neovacs - Novartis - Pfi zer - QLT - Repligen - Roche - Salix - Sanofi -Aventis - Santen - Schering-Plough - Serono - Shionogi - Shire - Stada - Teva - TolerRX - UCB - Wyeth - Xoma - ZymoGenetics Ordering: Order Online - visit http://www.researchandmarkets.com/reports/354463 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 22/08/2008 02:04:18 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Emerging Therapies to Treat Lupus Erythematosus Web Address: http://www.researchandmarkets.com/reports/354463 Office Code: OCHGFNQLUXU Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) - Single User €1,138.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 22/08/2008 02:04:18 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World